Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R John Simes

Showing results (31-40 of 80) with videos related to

Pageof 8
Sort By:
Journal of Cancer Research and Clinical Oncology|October 31, 2022
Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancerKatrin M Sjoquist, Andrew Martin, Nick Pavlakis, et al.
Future Oncology (London, England)|June 16, 2026
Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST programDerrick H W Siu, Frank P Y Lin, David M Thomas, et al.
Archives of Internal Medicine|July 11, 2007
Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trialJorik R Timmer, Jan Paul Ottervanger, Menko-Jan de Boer, et al.
Breast (Edinburgh, Scotland)|July 2, 2023
10-Year axillary recurrence in the RACS SNAC1 randomised trial of sentinel lymph node-based management versus routine axillary lymph node dissectionIan Campbell, Neil Wetzig, Owen Ung, et al.
The American Journal of Medicine|May 30, 2002
The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac eventsL Kristin Newby, Robert M Califf, Harvey D White, et al.
Psycho-Oncology|July 21, 2006
Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancerVlatka M Duric, Phyllis N Butow, Louise Sharpe, et al.
The Medical Journal of Australia|August 24, 2018
Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signal-seeking studies of targeted therapies for rare and neglected cancersSubotheni Thavaneswaran, Lucille Sebastian, Mandy Ballinger, et al.
Journal of Hypertension|December 11, 2002
Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatinMalcolm J West, Harvey D White, R John Simes, et al.
Patient Education and Counseling|April 25, 2008
Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancerVlatka M Duric, Phyllis N Butow, Louise Sharpe, et al.
Springerplus|September 12, 2013
Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisoneChee Khoon Lee, Val J Gebski, Alan S Coates, et al.
Pageof 8

Showing results (31-40 of 80) with videos related to

Sort By:
Pageof 8
Journal of Cancer Research and Clinical Oncology|October 31, 2022
Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancerKatrin M Sjoquist, Andrew Martin, Nick Pavlakis, et al.
Future Oncology (London, England)|June 16, 2026
Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST programDerrick H W Siu, Frank P Y Lin, David M Thomas, et al.
Archives of Internal Medicine|July 11, 2007
Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trialJorik R Timmer, Jan Paul Ottervanger, Menko-Jan de Boer, et al.
Breast (Edinburgh, Scotland)|July 2, 2023
10-Year axillary recurrence in the RACS SNAC1 randomised trial of sentinel lymph node-based management versus routine axillary lymph node dissectionIan Campbell, Neil Wetzig, Owen Ung, et al.
The American Journal of Medicine|May 30, 2002
The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac eventsL Kristin Newby, Robert M Califf, Harvey D White, et al.
Psycho-Oncology|July 21, 2006
Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancerVlatka M Duric, Phyllis N Butow, Louise Sharpe, et al.
The Medical Journal of Australia|August 24, 2018
Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signal-seeking studies of targeted therapies for rare and neglected cancersSubotheni Thavaneswaran, Lucille Sebastian, Mandy Ballinger, et al.
Journal of Hypertension|December 11, 2002
Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatinMalcolm J West, Harvey D White, R John Simes, et al.
Patient Education and Counseling|April 25, 2008
Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancerVlatka M Duric, Phyllis N Butow, Louise Sharpe, et al.
Springerplus|September 12, 2013
Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisoneChee Khoon Lee, Val J Gebski, Alan S Coates, et al.
Pageof 8